Banner image of a young Caucasian male with brown hair and a mustache wearing a white t-shirt. Not an actual patient.

APRETUDE OFFERS A DISCREET INJECTION SITE

APRETUDE is administered as a gluteal intramuscular injection by a healthcare professional every 2 months after 2 initiation injections administered one month apart.

Not actual patient.

Help provide HIV protection with each discreet, gluteal injection

APRETUDE is administered as an intramuscular injection by a healthcare provider every 2 months after initiation.

Immediately before starting your patients on APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, confirm HIV-1 negative status

Dosing*

INITIATION

Month 1
1 × 3 mL injection (600 mg)

Month 2
1 × 3 mL injection (600 mg)

CONTINUATION

Month 4 and every 2 months onwards
1 × 3 mL injection (600 mg)

Carefully select individuals who agree to the required injection, dosing, and testing schedule.

Counsel patients on PrEP adherence to help reduce the risk of HIV-1 infection and resistance development.

After the first injection, APRETUDE injections can be given up to 7 days before or after the target injection date.

*For patients concomitantly receiving rifabutin, please see full Prescribing Information for the adjusted recommended dosing schedule for APRETUDE.

Optional Oral Lead-in

An optional oral lead-in with oral cabotegravir may be taken prior to the initiation of APRETUDE to assess tolerability.

Optional Oral Lead-in

1 Month pre-injection
1 x 30 mg tablet of cabotegravir daily for ~1 month (at least 28 days)

INITIATION

Month 1
1 × 3 mL injection (600 mg)

Month 2
1 × 3 mL injection (600 mg)

CONTINUATION

Month 4 and every 2 months onwards
1 × 3 mL injection (600 mg)

Initiation injections should be administered on the last day of oral lead-in, if used, or within 3 days thereafter. 

See full Prescribing Information for details.

APRETUDE is delivered via intramuscular injection

Administration

Infographic depicting APRETUDE as a gluteal intramuscular injection.

APRETUDE is administered by a healthcare provider as a single 600-mg (3-mL) gluteal intramuscular injection at each visit.

Intramuscular injections deliver medication into muscle, not the subcutaneous layer. Longer needles are used so the drug reaches muscle tissue.

Use the z-track injection technique
Please see full APRETUDE Instructions for Use for complete administration instructions.

1. STRETCH THE SKIN

FIGURE A

Use the z-track injection technique to minimize medication leakage from the injection site.¹

Firmly drag the skin covering the injection site, displacing it by about an inch (2.5 cm). See Figure A.

Keep it held in this position for the injection.

2. INSERT THE NEEDLE

FIGURE B

Insert the needle to its full depth, or deep enough to reach the muscle. See Figure B.

3. INJECT THE DOSE OF MEDICINE

FIGURE C

Still holding the skin stretched, slowly press the plunger all the way down. See Figure C.

Ensure the syringe is empty.

Withdraw the needle and release the stretched skin immediately.

Injection Education

Preparing and Administering APRETUDE

Play video

FRAME 1: Opening

N/A

FRAME 2: Opening

This is an instructional video for the administration of APRETUDE.

Please see Important Safety Information for APRETUDE below on the web page. Please click on the link on the web page to view the full Prescribing Information, including the Boxed Warning and Instructions for Use for APRETUDE.

FRAME 3: Opening

Two topics will be reviewed in this video: Chapter 1 explains the preparation steps for APRETUDE, with Chapter 2 focusing on the steps for injection.

Please read the full Instructions for Use (IFU) contained in the APRETUDE Dosing Kit and available in the Prescribing Information at APRETUDEHCP.com.

FRAME 4: Opening

The information in this video is based on the APRETUDE Instructions for Use leaflet.

Where supplementary information is provided, a light bulb icon will appear to signify that this is the case.

FRAME 5: Opening

APRETUDE is available in a kit that includes a single-use vial of cabotegravir 600 milligrams per 3 milliliters extended-release injectable suspension. APRETUDE is for gluteal intramuscular use only and must be administered by a healthcare provider.

FRAME 6: Opening

A complete dose of APRETUDE requires 1 injection: 600 milligrams per 3 milliliters of cabotegravir. It does not need further dilution or reconstitution.

FRAME 7: Opening

APRETUDE should be stored in its original packaging at 36 degrees Fahrenheit to
77 degrees Fahrenheit until ready to use. APRETUDE does not require refrigeration.

FRAME 8: Cover

N/A

FRAME 9: Take the Dosing Kit

When removing the Dosing Kit from your office storage, you will find the following:

FRAME 10: Your Dosing Kit contains

An Instructions for Use leaflet
One single-dose vial containing 600 milligrams per 3 milliliters of cabotegravir. This vial has a brown tint to the glass with an orange cap
One 23-gauge, 1½-inch injection needle
One syringe and
One vial adapter

FRAME 11: Needle’s length

While the Dosing Kit contains a 23-gauge, 1½-inch needle, you should consider the patient’s build and use medical judgment to select an appropriate needle length.

FRAME 12: Needle’s length

Longer needle lengths may be required for individuals with higher BMI to ensure that the injection is administered intramuscularly as opposed to subcutaneously.

FRAME 13: You will also need

You will also require additional supplies not included in the packaging:

Non-sterile gloves
2 alcohol wipes
2 gauze pads
And a suitable sharps container.

FRAME 14: You will also need

An adhesive bandage may be used if bleeding occurs.

FRAME 15: Allow vial to come to room temperature

If the pack has been stored in the refrigerator, the vial should be brought to room temperature before you are ready to give the injection, but make sure the vial does not get above 86 degrees Fahrenheit.

Do not use any heating methods, other than using the warmth of your hands.

FRAME 16: Inspect vial

Before proceeding, inspect the vial. If the expiration date has passed

FRAME 17: Inspect vial

or if you can see foreign matter in the vial, do not use.

If the pack has been stored in the refrigerator, allow the medication to come to room temperature.

FRAME 18: Shake vigorously

N/A

FRAME 19: Shake vigorously

Hold it firmly and vigorously shake for a full 10 seconds as demonstrated to resuspend the contents.

FRAME 20: Inspect medicine

Next, invert the vial and check the suspension. Confirm the suspension is uniform. If it is not, shake the vial again. It is normal to see some small air bubbles.

FRAME 21: Remove vial cap

Next, remove the cap from the vial.

FRAME 22: Wipe rubber stopper

Wipe the rubber stopper with an alcohol wipe, and do not allow anything to touch it afterward.

FRAME 23: Peel open vial adapter

Peel off the paper backing from the vial adapter packaging in preparation for the next step.

FRAME 24: Peel open vial adapter

With the vial resting in an upright position on a flat surface,

FRAME 25: Attach vial adapter

press the vial adapter straight down onto the vial using the packaging, as shown.

The vial adapter should click securely into place.

FRAME 26: Attach vial adapter

When you are ready, lift off the vial adapter packaging.

FRAME 27: Prepare syringe withdrawing air

Remove the syringe from the packaging, and draw 1 milliliter of air into the syringe.

This will make it easier to draw up the medicine later. If this step is not completed, some medicine may flow back into the vial unintentionally, leaving less than intended in the syringe.

FRAME 28: Attach syringe and push air

With the vial on a flat surface, hold the vial adapter and vial firmly, as shown. Screw the syringe securely onto the vial adapter.

Press the plunger all the way down

FRAME 29: Attach syringe and push air

to push the air into the vial.

FRAME 30: Slowly draw up dose

Invert the syringe and vial and slowly withdraw as much of the medicine as possible into the syringe.

It is worth noting that there will be more medicine than the dose amount.

FRAME 31: Unscrew syringe

Hold the syringe plunger firmly in place as shown to prevent leakage. It is normal to feel some back pressure. Unscrew the syringe from the vial adapter, holding the vial adapter as shown. Check again that the medication looks uniform and milky white.

Once the medication has been drawn into the syringe, it is best to inject as soon as possible.

FRAME 32: Unscrew syringe

However, the medication can remain in the syringe for up to 2 hours before injecting. You must discard the medicine, syringe, and needle if this time limit is exceeded.

The filled syringe should not be placed in the refrigerator.

FRAME 33: Peel open needle packaging

Now, peel open the needle packaging part way to expose

FRAME 34: Peel open needle packaging

the needle base.

FRAME 35: Attach needle

While keeping the syringe upright, firmly twist the syringe onto the needle

FRAME 36: Attach needle

then finally remove the needle packaging from the needle.

FRAME 37: Cover

Now you're ready for the injection steps.

FRAME 38: Site Injections

The first step is to identify the injection site.

It is important to note that this injection is for gluteal intramuscular use only. Do not administer intravenously.

There are two possible sites for injection: the ventrogluteal and the upper outer quadrant of the dorsogluteal site. The injection should not be administered in any other site.

FRAME 39: Ventrogluteal site

The ventrogluteal site is recommended because it is located away from major nerves and blood vessels.

FRAME 40: Dorsogluteal site pop-up

You may also consider the upper outer quadrant of the dorsogluteal injection site, shown here, if preferred.

FRAME 41: Patient injection position pop-up

To receive an injection at the ventrogluteal site, the patient can lie in one of two positions. The first option for the patient is to lie on their side, with the knee bent.

The second option is to lie face down.

Regardless of the patient's body position, it is important to make sure that the muscle is relaxed prior to injection.

FRAME 42: Identify injection site pop-up

To locate the injection site,

FRAME 43: Identify injection site pop-up

place the heel of the hand over the patient’s greater trochanter

FRAME 44: Identify injection site pop-up

using the left hand for the patient's right hip or the right hand for the patient's left hip. Position the index finger on or toward the anterior superior iliac spine. Stretch the middle finger away from the index finger, creating a "V" or triangle.

FRAME 45: Identify injection site pop-up

The injection site is located within the triangle created by the index finger, the middle finger, and the iliac crest.

FRAME 46: Clean injection site

Clean the injection site with an alcohol wipe. Allow the skin to air dry before continuing. Once the site has been identified and the patient is in the correct position, you can proceed to administer the injection.

FRAME 47: Remove needle cap

Fold the needle guard away from the needle

FRAME 48: Remove needle cap

and pull off the injection needle cap.

FRAME 49: Remove extra medicine

Hold the syringe with the needle pointing up. Press the plunger to the 3-milliliter dosing mark to remove extra liquid and any air bubbles, ensuring you have the correct dose prepared.

FRAME 50: Z-track injection technique

Use the Z-track injection technique to minimize medication leakage from the injection site.

FRAME 51: Z-track injection technique

Firmly drag the skin covering the injection site, displacing it by about an inch.

Keep it held in this position for the injection.

FRAME 52: Insert needle

Insert the needle to its full depth or deep enough to reach the muscle.

FRAME 53: Inject the dose

Still holding the stretched skin, slowly press the plunger all the way down and ensure that the syringe is empty.

FRAME 54: Withdraw needle and release skin

Withdraw the needle and release the stretched skin immediately.

FRAME 55: Assess injection site pop-up

Once the needle has been removed, apply pressure to the injection site using gauze. Do not massage the area. A small adhesive bandage may be used if bleeding occurs.

FRAME 56: Make needle safe

Fold the needle guard over the needle.

Gently apply pressure using a hard surface to lock the needle guard in place.

FRAME 57: Make needle safe

The needle guard will make a click when it locks.

FRAME 58: Dispose safely

Dispose of the used needle, syringe, vial, and adapter

FRAME 59: Dispose safely

according to local health and safety laws.

FRAME 60: Closing

Thank you for watching this step-by-step guide for the preparation and injection of APRETUDE. For more information, visit APRETUDEHCP.com.

Please see link to full Prescribing Information, including Boxed Warning, for APRETUDE on this website

FRAME 61: References

N/A

HIV-1 testing

Screen all individuals with a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection

Before starting APRETUDE or oral cabotegravir
With each subsequent injection
Upon diagnosis of any other STI
When recent exposure to HIV is suspected or clinical symptoms consistent with HIV-1 are present

Recommendations following an antigen/antibody test

If an antigen/antibody-specific test is used and the result is:

Negative

Confirm using an RNA-specific assay (before or after APRETUDE administration)

Positive

Transition to a complete HIV-1 treatment

Maintaining the dosing schedule and required HIV testing at injection appointments can help support communication with patients. Each visit can provide opportunities to counsel patients on adherence to the administration schedule, additional prevention measures like using condoms, and the importance of knowing their partner's status and testing for other STIs.²

When a payer covers PrEP, HIV testing should also be covered.³ The payer or your lab can help you understand which tests may be covered and available.

FDA=US Food and Drug Administration; PrEP=pre-exposure prophylaxis; RNA= ribonucleic acid; STI=sexually transmitted infection.

APRETUDE's drug-drug interaction profile has been well-characterized

The table below includes potentially significant interactions but is not exhaustive. These recommendations are based on studies conducted with oral cabotegravir or predicted interactions due to the expected magnitude of the interaction. Please refer to the full Prescribing Information for additional important context regarding potential drug interactions with APRETUDE.

^‡Drugs that are strong inducers of UTG1A1 or 1A9 are expected to decrease cabotegravir plasma concentrations; therefore, administration of APRETUDE with these drugs is contraindicated. Consider the potential for drug interactions prior to, during use of, and after discontinuation of APRETUDE.

Drug-drug Interaction Education

Managing DDIs in LAI PrEP

Play video

ACTION: Background music plays as all three speakers chat and receive drinks. Title content appears on screen.

SUPER:

Expert and Patient Perspectives

Managing DRUG-DRUG INTERACTIONS WITH LAI PrEP

[Dr Mohamed] This is so much more fun. I love that side of you, pharma mama.

ACTION: Speakers on frame and content will animate onto frame.

SUPER:

NASSER MOHAMED, MD has been compensated by ViiV Healthcare.

LEO A real patient sharing their personal experience who has been compensated by ViiV Healthcare. Individual results may vary.

CHRISTINA HARBISON, PharmD has been compensated by ViiV Healthcare.

ViiV Healthcare logo

[Dr Mohamed] Thank you for being here. And thank you for tuning in.

ACTION: Speakers and content on frame, content leaves frame shortly thereafter.

SUPER:

NASSER MOHAMED, MD has been compensated by ViiV Healthcare

LEO A real patient receiving APRETUDE and has been compensated by ViiV Healthcare

CHRISTINA HARBISON, PharmD has been compensated by ViiV Healthcare

ViiV Healthcare logo

[Dr Mohamed] My name is Dr Nas, and I'm joined by Dr Harbison and our patient ambassador, Leo.

[Dr Harbison] Today we're going to discuss drug-drug interactions with long-acting injectable PrEP. Throughout, you'll hear from both providers and patients on how these considerations play out in the real world.

[Dr Mohamed] And to connect the topic to real stories, we're going to start with our patient ambassador Leo and hear about their journey.

ACTION: Speakers on frame.

SUPER:

ViiV Healthcare logo

[Leo] Well, I feel like I’ve lived many lives. Growing up in a small, rural town, I had a pretty normal childhood. I played lots of sports, worked a lot of jobs. Had relationships with boys that remain, you know, pretty surface level. And I didn't yet have the language for who I was becoming. At 19, I found myself in a spiral of active addiction, a toxic relationship, and reckless behavior.

ACTION: Speakers on frame.

SUPER:

ViiV Healthcare logo

[Leo] After we [my girlfriend and I] broke up, I started sleeping around without using protection, simply just because I didn't really know the forms of protection other assigned female birth individuals could use with each other.

ACTION: Speakers on frame.

SUPER:

ViiV Healthcare logo

[Leo] I didn’t care much about anything or anyone, much less myself. I started working in the sex industry, primarily in strip clubs. And after a couple years of reckless living, I found myself in rehab at 21. During that time, I reflected on my past choices. And when I got out, I decided it was time to take care of myself.

Once back on my feet, I got an HIV test and was absolutely terrified to get the results, given my sexual behavior over the previous few years. My result was negative though, and that was the first time someone talked to me about PrEP as an AFAB individual.

ACTION: Speakers on frame.

SUPER:

ViiV Healthcare logo

[Dr Mohamed] Thank you for sharing all of that with us. I know it's quite intimate, and not a lot of people have the ability to put this out, let alone share it with an audience. So, I want to acknowledge that.

[Leo] Thank you.

[Dr Harbison] I’m glad you shared your story.

ACTION: Speakers on frame.

SUPER:

ViiV Healthcare logo

[Dr Mohamed] When I see the patient, I let them know sometimes up-front that there is not anything that you're doing or not doing that will make me disengage from your care.

[Dr Harbison] That's a great way to approach patients. I'm going to take that back and use it in my clinics.

ACTION: Speakers on frame, content will animate onto frame.

SUPER:

Please see accompanying full Prescribing Information, including Boxed Warning, for APRETUDE.

APRETUDE logo

[Dr Mohamed] Great. When I prescribe a PrEP option for my patients for HIV prevention, APRETUDE is often on the table.

ACTION: ISI animates onto frame; animated graphic for video countdown will appear.

SUPER:

INDICATION

APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.

Please see Important Safety Information for APRETUDE throughout.
Please see accompanying full Prescribing Information, including Boxed Warning, for APRETUDE.

APRETUDE logo

[Voiceover] APRETUDE is indicated for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg or 77 pounds who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE.

ACTION: ISI animates onto frame; animated graphic for video countdown will appear.

SUPER:

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION

Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen.

Please see Important Safety Information for APRETUDE throughout.
Please see accompanying full Prescribing Information, including Boxed Warning, for APRETUDE.

APRETUDE logo

[Voiceover] Now we’ll cover the Important Safety Information for APRETUDE.

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION

Individuals must be tested and confirmed to be HIV negative prior to starting PrEP with either oral or long-acting injectable cabotegravir and with each subsequent injection of APRETUDE. The test used to screen for HIV should be approved or cleared by the FDA for diagnosis of acute or primary HIV-1. Drug-resistant HIV variants have been identified with use of APRETUDE in the presence of undiagnosed infection. If a person becomes infected with HIV while receiving APRETUDE, they must transition to a complete HIV treatment regimen.

ACTION: ISI animates onto frame; animated graphic for video countdown will appear.

SUPER:

IMPORTANT SAFETY INFORMATION (cont’d)

CONTRAINDICATIONS

Do not use APRETUDE in individuals:
with unknown or positive HIV-1 status
with previous hypersensitivity reaction to cabotegravir
receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine

Please see Important Safety Information for APRETUDE throughout.
Please see accompanying full Prescribing Information, including Boxed Warning, for APRETUDE.

APRETUDE logo

[Voiceover] APRETUDE is contraindicated in those with unknown or positive HIV status. Additionally, do not use APRETUDE in people who have had a hypersensitivity reaction to cabotegravir or in combination with the medicines listed on the slide.

ACTION: Speakers on frame.

SUPER:

APRETUDE logo

[Dr Mohamed] What are your thoughts about drug-drug interactions when it comes to long-acting injectable PrEP medications?

[Dr Harbison] So, it's very important to consider because the medications lower the concentration of APRETUDE, also YEZTUGO, in their bloodstream. So, what happens when PrEP doesn't work? You can contract HIV.

ACTION: Speakers on frame.

SUPER:

APRETUDE logo

[Leo] Yeah.

[Dr Mohamed] And also, when we talk about drug-drug interactions, we're not necessarily only talking about prescription drugs, right? We're talking about an over-the-counter supplement that people might be taking. Or it could be a recreational drug that people are using.

So, these are important conversations, because that interaction [can] happen in both ways. It doesn't only lower and decrease the efficacy of the PrEP drug that we're taking, but it may increase the toxicity profile of the other drugs that we're taking.

ACTION: Speakers on frame.

SUPER:

APRETUDE logo

[Dr Harbison] Given the long-acting nature of injectable PrEP, it's important to educate patients on drug-drug interactions.

ACTION: Content animates full screen onto the frame.

SUPER:

DRUG-DRUG INTERACTIONS AND LONG-ACTING INJECTABLE PrEP

EFFECT OF OTHER DRUGS ON APRETUDE (cabotegravir)

APRETUDE Prescribing Information includes the below information on contraindicated drugs.

APRETUDE is primarily metabolized by UGT1A1 with some contribution from UGT1A9. Drugs that are strong inducers of UGT1A1 or 1A9 are expected to decrease cabotegravir plasma concentrations; therefore, coadministration of APRETUDE with these drugs is contraindicated.

Contraindicated strong UGT1A1 and UGT1A9 inducers from APRETUDE PI:
carbamazepine (TEGRETOL)
oxcarbazepine (OXTELLAR)
phenobarbital (LUMINAL)
phenytoin (DILANTIN)
rifampin (RIFADIN)
rifapentine (PRIFTIN)

APRETUDE dosage adjustments with rifabutin

Supplemental doses of APRETUDE are recommended with concomitant use of rifabutin, an anti-mycobacterial. Please see APRETUDE PI for additional dosing recommendations.

EFFECT OF OTHER DRUGS ON YEZTUGO (lenacapavir)

YEZTUGO Prescribing Information has no listed contraindicated drugs.¹

YEZTUGO is metabolized by CYP3A and UGT1A1 (minor). Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended.¹

Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers.¹

Examples of strong or moderate CYP3A inducers (non-exhaustive)^2,3:
dexamethasone (DECADRON)
rifampin (RIFADIN)
phenytoin (DILANTIN)
carbamazepine (TEGRETOL)
phenobarbital (LUMINAL)

YEZTUGO dosage adjustments with strong or moderate CYP3A inducers

Supplemental doses of YEZTUGO are recommended for individuals initiating therapy with either strong or moderate CYP3A inducers.¹ You can find a non-exhaustive list of CYP3A inducers above. Please see YEZTUGO PI for additional dosing recommendations.

EFFECT OF YEZTUGO ON OTHER DRUGS

YEZTUGO is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administration of YEZTUGO with sensitive substrates of CYP3A or P-gp may increase the concentrations of these substrates and result in the increased risk of their adverse events.¹ See the prescribing information of these sensitive substrates for dosing recommendations or appropriate monitoring of safety.

Examples of CYP3A substrates (non-exhaustive)^2,3:
fentanyl (DURAGESIC)
oxycodone (OXYCONTIN/PERCOCET)
salmeterol (ADVAIR)
sildenafil (VIAGRA)
simvastatin (ZOCOR)
budesonide (PULMICORT)
buspirone (BUSPAR)
quetiapine (SEROQUEL)
felodipine (PLENDIL)
alprazolam (XANAX)
apixaban (ELIQUIS)
clonazepam (KLONOPIN)
diazepam (VALIUM)
fluticasone (FLONASE)
tadalafil (CIALIS)
warfarin (COUMADIN)
rivaroxaban (XARELTO)
amlodipine (NORVASC)
saxagliptin (ONGLYZA)
fludrocortisone (FLORINEF)

Examples of P-gp substrates (non-exhaustive)^2,3:
fexofenadine (ALLEGRA)
digoxin (DIGITEK)
edoxaban (SAVAYSA)
dabigatran (PRADAXA)
apixaban (ELIQUIS)

No comparative efficacy or safety conclusions can be drawn from these tables.

Potential drug interactions for APRETUDE and YEZTUGO are primarily based on the pharmacokinetic properties of each drug, and specific drug interaction studies may not have been conducted for each interaction.¹This is not intended to compare safety or efficacy of the products. The examples provided are for ease of reference, and the lists included are not exhaustive and may not include all potential drug interactions. Not all DDIs have the same impact; clinicians should carefully weigh the risks versus benefits.

1. YEZTUGO. Prescribing Information. Gilead Sciences, Inc.; 2025. 2. For healthcare professionals: FDA’s examples of drugs that interact with CYP enzymes and transporter systems. FDA.gov. Updated June 27, 2025. Downloaded September 10, 2025. https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems 3. Liverpool HIV drug interaction checker. Accessed September 10, 2025. https://www.hiv-druginteractions.org/checker

APRETUDE logo

[Dr Harbison] Both APRETUDE and YEZTUGO offer long-acting HIV protection. But they have distinct metabolic pathways and pharmacologic profiles. There is potential for other drugs to affect both APRETUDE and YEZTUGO.

ACTION: Content zooms into “EFFECT OF OTHER DRUGS ON APRETUDE.”

SUPER:

DRUG-DRUG INTERACTIONS AND LONG-ACTING INJECTABLE PrEP

EFFECT OF OTHER DRUGS ON APRETUDE (cabotegravir)

APRETUDE Prescribing Information includes the below information on contraindicated drugs.

APRETUDE is primarily metabolized by UGT1A1 with some contribution from UGT1A9. Drugs that are strong inducers of UGT1A1 or 1A9 are expected to decrease cabotegravir plasma concentrations; therefore, coadministration of APRETUDE with these drugs is contraindicated.

Contraindicated strong UGT1A1 and UGT1A9 inducers from APRETUDE PI:
carbamazepine (TEGRETOL)
oxcarbazepine (OXTELLAR)
phenobarbital (LUMINAL)
phenytoin (DILANTIN)
rifampin (RIFADIN)
rifapentine (PRIFTIN)

APRETUDE dosage adjustments with rifabutin

Supplemental doses of APRETUDE are recommended with concomitant use of rifabutin, an anti-mycobacterial. Please see APRETUDE PI for additional dosing recommendations.

No comparative efficacy or safety conclusions can be drawn from these tables.

Potential drug interactions for APRETUDE and YEZTUGO are primarily based on the pharmacokinetic properties of each drug, and specific drug interaction studies may not have been conducted for each interaction.¹This is not intended to compare safety or efficacy of the products. The examples provided are for ease of reference, and the lists included are not exhaustive and may not include all potential drug interactions. Not all DDIs have the same impact; clinicians should carefully weigh the risks versus benefits.

1. YEZTUGO. Prescribing Information. Gilead Sciences, Inc.; 2025. 2. For healthcare professionals: FDA’s examples of drugs that interact with CYP enzymes and transporter systems. FDA.gov. Updated June 27, 2025. Downloaded September 10, 2025. https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems 3. Liverpool HIV drug interaction checker. Accessed September 10, 2025. https://www.hiv-druginteractions.org/checker

APRETUDE logo

[Dr Harbison] APRETUDE is primarily metabolized through UGT1A1, with some contribution from UGT1A9. Coadministration from the drugs listed on the screen, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine, is contraindicated. If your patient is taking rifabutin, refer to APRETUDE Prescribing Information for dose adjustments.

ACTION: Content zooms into “EFFECT OF OTHER DRUGS ON YEZTUGO.”